Organization
Innate Immunotherapeutics
Australian biotechnology company that was developing the multiple sclerosis drug MIS416.
Connections 2
board members
- Chris Collins Primary record 1
involved in
- Chris Collins insider-trading case the company whose failed drug trial was the inside information Primary record 1
Proof 1 source
-
Congressman Christopher Collins Pleads Guilty To Insider Trading Scheme And Lying To Federal Law Enforcement Agents (press release), U.S. Department of Justice, 1 Oct 2019.
Primary record
Archived copy
in addition to serving on the board of directors of Innate Immunotherapeutics (“Innate”), an Australian biotechnology company, was also one of Innate’s largest shareholders
MIS416 – a multiple sclerosis drug that Innate was developing – had failed a critical drug trial
Page history 1 change
- Add 55 stories, each checked against its sources96e92fe6
Something wrong or missing? Tell us, with a source, or edit this page.